Dr. Melya Hughes Crameri joined Ventac Partners in February 2015. She brings over 20 years of experience in the life science industry both in the United States and Europe, working primarily with early stage companies and academic innovation.
Melya has served as a consultant to multiple early stage companies in the US, UK, Switzerland and Italy. Prior to Joining Ventac Partners, she was Founder & CEO of Caltherix Inc. a peptide-based technology spin-out of Amunix Inc. She served as VP Alliances & Intellectual Property of Evolva SA, a synthetic biology company, from Series A to its exit on the SIX Swiss Exchange (SIX:EVE), and was Founder & CEO of Genetic Chemistry Inc. (Evolva’s US subsidiary), securing multi-million dollar discovery contracts and supporting $50M in venture funding. Previously, she served as Head of Licensing and Patents, Novartis Research Foundation (FMI) developing and executing on their first patent and business strategy. Her executive experience has crossed multiple functional areas including fundraising, business development, strategic alliances, operations, intellectual property and licensing.
Earlier in her career, she was trained in intellectual property at Cooley Godward LLP before joining Geron Corp. as in-house counsel. She is a European Patent Attorney and a U.S Patent Agent. She worked as a postdoctoral scientist at IRBM (MSD), Italy and the FMI (Ciba-Geigy), Switzerland after earning her BSc (Hons.) in Biochemistry from Cardiff University, UK and her PhD in Biochemistry from the University of Basel, Switzerland.